Condition
EGFR-mutated NSCLC clinical trials and research
As of November 12, 2026, Find a Trial lists 2 EGFR-mutated NSCLC clinical trials that are recruiting, at sites in 4 countries (most in Australia (1), Canada (1), United States (1)). By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 4Countries
All recruiting trials (2)
-
Reasons for recurrence after adjuvant osimertinib in surgically removed EGFR-mutated lung cancer
This project looks for genetic and clinical reasons why people with EGFR-mutated lung cancer who had surgery and adjuvant osimertinib later had their cancer come back, using tissue and blood samples taken at recurrence.
-
Combining ORIC-114 with Amivantamab for NSCLC with EGFR Exon 20 Insertion Mutations
This study is testing a new combination of two drugs, ORIC-114 and amivantamab, to see if they can help people with advanced lung cancer that has a specific genetic mutation.
Related topics
Quick answers
How many EGFR-mutated NSCLC clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in Australia (1 trial), Canada (1 trial), United States (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.